Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Beyondspring Pharmaceuticals Inc. currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 3 pending office actions are distributed across 3 distinct examiners and 3 distinct art units. This distribution indicates that the company's current patent activities are being reviewed by 3 distinct art units within the patent office, potentially reflecting a range of technical applications within the biotechnology sector.
The busiest examiner for the portfolio is KIFLE, BRUCK, who is currently handling 1 busiest examiner pending office action. The 1 busiest examiner pending office action is part of the 3 pending office actions currently on record. With 3 distinct examiners involved, practitioners must adapt their prosecution strategies to the specific guidelines of each individual. The presence of 3 distinct examiners means that the company's outcomes are not dependent on this individual's interpretation of the prior art.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +36.1% |
| HUANG, GIGI GEORGIANA | 1 | 31.8% | +30.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18554595 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING TUMORS | PECKHAM, RICHARD GRANT | 26d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18554595 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING TUMORS | PECKHAM, RICHARD GRANT | 26d |
| 16966156 | COMPOSITION AND METHOD FOR REDUCING CHEMOTHERAPY-INDUCED NEUTROPENIA VIA THE ADMINISTRATION OF PLINABULIN AND A G-CSF AGENT | HUANG, GIGI GEORGIANA | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18554595 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING TUMORS | PECKHAM, RICHARD GRANT | 1627 | §103§112Other | Non-Final OA | 26d | Pending | Oct 09, 2023 |
| 16966156 | COMPOSITION AND METHOD FOR REDUCING CHEMOTHERAPY-INDUCED NEUTROPENIA VIA THE ADMINISTRATION OF PLINABULIN AND A G-CSF AGENT | HUANG, GIGI GEORGIANA | 1613 | §103§112DP | Non-Final OA | — | Pending | Jul 30, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBeyondspring Pharmaceuticals Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Richard Grant Peckham has the most, with 1 of Beyondspring Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
